NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease

Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease

Comparative Effectiveness Reviews, No. 18

Investigators: , PharmD, , PharmD, BCPS, , MD, FACC, , PharmD, , PharmD, , MS, , MS, , MS, and , PharmD, FCP, FCCP.

University of Connecticut/Hartford Hospital Evidence-based Practice Center
Rockville (MD): Agency for Healthcare Research and Quality (US); .
Report No.: 10-EHC002-EF

Excerpt

This is an evidence report prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center (EPC) concerning the benefits and harms associated with using angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), either alone or in combination, in people with stable ischemic heart disease or ischemic heart disease risk equivalents and intact left ventricular systolic function.

While the role of ACE inhibitors and ARBs in patients with post-myocardial infarction left ventricular dysfunction or chronic heart failure is well established, the role for these modalities in patients with stable ischemic heart disease or ischemic heart disease risk equivalents and preserved left ventricular systolic function is not as clear. The aim of this report is to acquire, assess, and summarize the current evidence about the benefits and harms associated with the use of ACE inhibitors and ARBs, either alone or in combination, in this patient population. The information is intended to inform clinicians, payors, and the public, while helping to define avenues for future research.

Contents

540 Gaither Road, Rockville, MD 20850. www​.ahrq.gov

Prepared for: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.1 Contract No. 290-2007-10067-I. Prepared by: University of Connecticut/Hartford Hospital Evidence-based Practice Center.

Suggested citation:

Coleman CI, Baker WL, Kluger J, Reinhart K, Talati R, Quercia R, MatherJ, Giovenale S, White CM. Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease. (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I.) Rockville, MD: Agency for Healthcare Research and Quality. October 2009. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.

This report is based on research conducted by the University of Connecticut/Hartford Hospital Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. 290-2007-10067-I). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

Craig I. Coleman, Pharm.D., has been a primary investigator on projects sponsored by Boehringer-Ingelheim Pharmaceuticals, the makers of the angiotensin receptor blocker telmisartan, but none of the projects were related to ischemic heart disease, angiotensin receptor blockers, or telmisartan. Dr. Coleman was not involved in the data extraction, analysis, or synthesis of the two key questions involving trials including telmisartan. None of the other investigators has any affiliations or financial involvement that conflicts with the material presentedin this report.

1

540 Gaither Road, Rockville, MD 20850. www​.ahrq.gov

Bookshelf ID: NBK36476PMID: 20704041
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (5.0M)
  • Disable Glossary Links

Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...